Search

Search Constraints

You searched for: Author/Creator Galera, Carlos

Search Results

1. Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. Issue 1 (December 2018)

2. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. Issue 24 (17th June 2022)

3. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. Issue 8 (August 2020)

4. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. (2nd March 2022)

6. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. (1st August 2020)

7. Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response. (1st November 2021)

8. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. (1st February 2019)

9. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. (November 2021)

10. Standard Method Performance Requirements (SMPRs®) 2017.021: Quantitation of Wheat, Rye, and Barley Gluten in Oats. (23rd November 2019)